Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies
- PMID: 11382917
- DOI: 10.1002/jcp.1095
Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies
Abstract
Endoglin (CD105) is a cell membrane glycoprotein over-expressed on highly proliferating endothelial cells in culture, and on endothelial cells of angiogenetic blood vessels within benign and malignant tissues. CD105 binds several factors of the Transforming Growth Factor (TGF)-beta superfamily, and its over-expression modulates cellular responses to TGF-beta1. The complex of experimental findings accumulated in the last few years strongly indicate that CD105 is a powerful marker of angiogenesis, and that it might play a critical role in the pathogenesis of vascular diseases and in tumor progression. In this paper, we will review the structural, biological and functional features of CD105, as well as its distribution within normal and neoplastic tissues, emphasizing its foreseeable role as a molecular target for new diagnostic and bioimmunotherapeutic approaches in human malignancies.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
-
Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.Curr Cancer Drug Targets. 2003 Dec;3(6):427-32. doi: 10.2174/1568009033481741. Curr Cancer Drug Targets. 2003. PMID: 14683500 Review.
-
Endoglin (CD105): a target for anti-angiogenetic cancer therapy.Curr Drug Targets. 2003 May;4(4):291-6. doi: 10.2174/1389450033491073. Curr Drug Targets. 2003. PMID: 12699349 Review.
-
Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.Oncogene. 2003 Sep 29;22(42):6557-63. doi: 10.1038/sj.onc.1206813. Oncogene. 2003. PMID: 14528280 Review.
-
Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.Clin Cancer Res. 2008 Apr 1;14(7):1931-7. doi: 10.1158/1078-0432.CCR-07-4478. Clin Cancer Res. 2008. PMID: 18381930 Review.
-
Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma.Br J Cancer. 1996 Nov;74(10):1586-91. doi: 10.1038/bjc.1996.593. Br J Cancer. 1996. PMID: 8932339 Free PMC article.
Cited by
-
Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905).Br J Cancer. 2004 Mar 22;90(6):1216-21. doi: 10.1038/sj.bjc.6601452. Br J Cancer. 2004. PMID: 15026804 Free PMC article.
-
Angiogenesis in salivary carcinomas with and without myoepithelial differentiation.Virchows Arch. 2008 Oct;453(4):359-67. doi: 10.1007/s00428-008-0664-z. Epub 2008 Sep 16. Virchows Arch. 2008. PMID: 18795324
-
Long term expansion profile of mesenchymal stromal cells at protein nanosheet-stabilised bioemulsions for next generation cell culture microcarriers.Mater Today Bio. 2021 Nov 16;12:100159. doi: 10.1016/j.mtbio.2021.100159. eCollection 2021 Sep. Mater Today Bio. 2021. PMID: 34841241 Free PMC article.
-
An Accessible Organotypic Microvessel Model Using iPSC-Derived Endothelium.Adv Healthc Mater. 2018 Jan;7(2):10.1002/adhm.201700497. doi: 10.1002/adhm.201700497. Epub 2017 Aug 7. Adv Healthc Mater. 2018. PMID: 29364596 Free PMC article.
-
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.J Matern Fetal Neonatal Med. 2008 Jan;21(1):9-23. doi: 10.1080/14767050701830480. J Matern Fetal Neonatal Med. 2008. PMID: 18175241 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases